|
Post by mannmade on Apr 14, 2020 23:43:44 GMT -5
As I recall while they originally thought they might use this insulin for Afrezza, but after the amphastar deal, it was decided better to resell this insulin at some point, since no one was exactly clear on the shelf life. I beleive it was kept on the books but ultimately not to be used for Afrezza.
|
|
|
Post by mannmade on Apr 14, 2020 0:13:32 GMT -5
Well as I recall they do not have a Compliance Officer anymore...
|
|
|
Post by mannmade on Apr 13, 2020 23:27:37 GMT -5
Only ultra rapid acting inhaled insulin. Why do you say that? What non injectable insulins are promoted as “ultra rapid”? Apridia.
|
|
|
Post by mannmade on Apr 13, 2020 23:26:52 GMT -5
Now can the reps tell docs that AFREZZA is the ONLY ultra rapid acting insulin? That is the real question for me... GLTAL’s!!! Forgot to add also hope this means there was a label expansion and that it will be reflected in the SOC by the ADA.
|
|
|
Post by mannmade on Apr 13, 2020 20:13:28 GMT -5
Now can the reps tell docs that AFREZZA is the ONLY ultra rapid acting insulin? That is the real question for me... GLTAL’s!!!
|
|
|
Post by mannmade on Apr 2, 2020 14:53:18 GMT -5
you are correct holdem
|
|
|
Post by mannmade on Apr 1, 2020 15:35:30 GMT -5
And I’m not negative about us getting to break even. I am negative about how we’re getting there and at who’s expense. Big changes needed! Harry’s post on ST, “ I'm just as irritated as the rest of you, but authorizing shares doesn't mean immediate dilution. However, we have seen what the management & BoDs has done with the last package of shares authorized. We need to see some major buying by the top executive team IMO and I would also like to see bonuses stopped for 2020 and voluntary pay cut by the CEO.” I fully agree with that. ( Also mentioned was this... Also, someone with nads needs to sell Danbury's manufacturing capabilities as a priority to Onshore BP manufacturing. Moving headquarters to Danbury.) With this I think people would be more positive about voting for more shares. Several CEO's of major American Companies like Yum Brands have agreed to take no compensation for the rest of 2020. Something for Mnkd to think about...
|
|
|
Post by mannmade on Mar 19, 2020 18:10:59 GMT -5
Actually smart idea. They get good press and get paid by govt to lease ship and defray ant maintenance expenses on assets not able to use.
|
|
|
Post by mannmade on Mar 19, 2020 15:01:10 GMT -5
Someone just bought 17k and then 170k shares at close.
|
|
|
Post by mannmade on Mar 19, 2020 12:04:05 GMT -5
I believe Afrezza is 70% or so as it reaches the deep lungs which may be one major difference here. The more educated scientists on this board may correct me if I am wrong.
|
|
|
Post by mannmade on Mar 17, 2020 11:20:08 GMT -5
That would hurt Midcap as well.
|
|
|
Post by mannmade on Mar 7, 2020 14:46:57 GMT -5
I suppose it could be true but then who is it benefitting as it ramps up uncontrolled with no known cure or vacine. Seems even politicians are not immune... especially in Iran... We are just not meant to eat certain animals anymore as the world becomes truly interconnected... Think ebola...
|
|
|
Post by mannmade on Mar 3, 2020 19:22:05 GMT -5
And don't forget Michael Pfeffer...
|
|
|
Post by mannmade on Mar 1, 2020 12:56:58 GMT -5
At the 2015 ASM Sanofi's big excuse for not selling afrezza was the spirometer requirement. Al brought with him a handheld device which was about $400. We got into a discussion about Jones marketing the afrezza spirometer. Soon after Al's health got bad so I don't think he ever put a deal together. Jone's is still selling the afrezza spirometer www.jonesmedical.com/spirometry-for-afrezza/I wonder why no spirometry testing for tobacco, weed, even asthma meds, why just Mannkinds Afrezza. IMHO, likley because of the frequency of use, eg: up to six doses a day if use for three meals and require a follow up. Others are much less frequent I beleive, except perhaps weed... GLTAL's
|
|
|
Post by mannmade on Feb 28, 2020 19:01:43 GMT -5
Could be associated with UTHR. Certainly not sales goals associated with Afrezza.
|
|